Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -104.42% is 93% below its 5-year average of -54.19%, near the low end of its 5-year range (-113.60%–-27.97%).
35.73% below its 12-month average of -76.93%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -19.83%.
RETURN ON ASSETS (ROA)
-104.42%
RETURN ON ASSETS (ROA) AVG TTM
-76.93%
RETURN ON ASSETS (ROA) AVG 3Y
-55.08%
RETURN ON ASSETS (ROA) AVG 5Y
-54.19%
RETURN ON ASSETS (ROA) AVG 10Y
-86.62%
RETURN ON ASSETS (ROA) AVG 15Y
-42.04%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-35.73%
CURRENT VS 3Y AVG
-89.56%
CURRENT VS 5Y AVG
-92.69%
CURRENT VS 10Y AVG
-20.54%
CURRENT VS 15Y AVG
-148.40%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.94%
median of 845 covered companies
CURRENT VS SECTOR MEDIAN
-226.93%
vs the sector median at left
Larimar Therapeutics, Inc.
Market Cap
$290.87M
Return on Assets (ROA)
-104.42%
TTM Avg
-76.93%
3Y Avg
-55.08%
5Y Avg
-54.19%
Market Cap
$286.75M
Return on Assets (ROA)
-13.93%
TTM Avg
-17.93%
3Y Avg
-26.92%
5Y Avg
-24.25%
Market Cap
$285.99M
Return on Assets (ROA)
-17.87%
TTM Avg
-36.13%
3Y Avg
-48.35%
5Y Avg
-41.88%
Market Cap
$285.55M
Return on Assets (ROA)
-35.03%
TTM Avg
-13.04%
3Y Avg
-43.14%
5Y Avg
-55.84%
Market Cap
$283.11M
Return on Assets (ROA)
-128.66%
TTM Avg
-214.31%
3Y Avg
-145.75%
5Y Avg
-133.94%
Market Cap
$283.18M
Return on Assets (ROA)
-48.34%
TTM Avg
-34.05%
3Y Avg
-4876.46%
5Y Avg
-3907.18%
Market Cap
$281.92M
Return on Assets (ROA)
-26.24%
TTM Avg
-12.09%
3Y Avg
-27.60%
5Y Avg
-33.24%
Market Cap
$280.91M
Return on Assets (ROA)
-18.18%
TTM Avg
-10.00%
3Y Avg
-29.10%
5Y Avg
-54.94%
Market Cap
$301.90M
Return on Assets (ROA)
-96.57%
TTM Avg
-96.57%
3Y Avg
-96.57%
5Y Avg
-96.57%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | $290.87M | -104.42% | -76.93% | -55.08% | -54.19% |
| Standard BioTools Inc. (LAB)vs › | $286.75M | -13.93% | -17.93% | -26.92% | -24.25% |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.99M | -17.87% | -36.13% | -48.35% | -41.88% |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | -35.03% | -13.04% | -43.14% | -55.84% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $283.11M | -128.66% | -214.31% | -145.75% | -133.94% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $283.18M | -48.34% | -34.05% | -4876.46% | -3907.18% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | -26.24% | -12.09% | -27.60% | -33.24% |
| Aurora Cannabis Inc. (ACB)vs › | $280.91M | -18.18% | -10.00% | -29.10% | -54.94% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $301.90M | -96.57% | -96.57% | -96.57% | -96.57% |
| Benitec Biopharma Inc. (BNTC)vs › | $302.32M | -24.94% | -31.51% | -135.72% | -152.11% |
ROA
-104.4%
ROE
-135.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -113.60% |
| 2024-12-31 | -40.26% |
| 2023-12-31 | -38.51% |
| 2022-12-31 | -27.97% |
| 2021-12-31 | -64.37% |
| 2020-12-31 | -40.43% |
| 2019-12-31 | -444.76% |
| 2018-12-31 | -50.40% |
| 2017-12-31 | -49.31% |
| 2016-12-31 | -43.97% |
| 2015-12-31 | -39.28% |
| 2014-12-31 | -31.12% |
| 2013-12-31 | -36.78% |
| 2012-12-31 | -126.34% |
| 2011-12-31 | 0.00% |
